首页> 外文期刊>Pediatric clinics of North America >Defects in surfactant synthesis: clinical implications.
【24h】

Defects in surfactant synthesis: clinical implications.

机译:表面活性剂合成中的缺陷:临床意义。

获取原文
获取原文并翻译 | 示例
       

摘要

Since the original description of deficiency of the pulmonary surfactant in premature newborn infants by Avery and Mead in 1959, respiratory distress syndrome has most commonly been attributed to developmental immaturity of surfactant production. Studies of different ethnic groups, gender, targeted gene ablation in murine lineages, and recent clinical reports of monogenic causes of neonatal respiratory distress syndrome have demonstrated that genetic defects disrupt pulmonary surfactant metabolism and cause respiratory distress syndrome, especially in term or near-term infants and in older infants, children, and adults. In contrast to developmental causes of respiratory distress, which may improve as infants and children mature, genetic causes result in both acute and chronic (and potentially irreversible) respiratory failure.
机译:自从1959年Avery和Mead最初描述过早产儿缺乏肺表面活性物质以来,呼吸窘迫综合征最常归因于表面活性物质生产的发育不成熟。对不同种族,性别,鼠类谱系中靶向性基因消融的研究以及新生儿呼吸窘迫综合征单基因病因的最新临床报告表明,遗传缺陷破坏了肺表面活性物质的代谢并导致了呼吸窘迫综合征,尤其是足月或近期婴儿以及较大的婴儿,儿童和成人。与发展成因的呼吸窘迫病相反,随着婴儿和儿童的成长,这种情况可能会有所改善,而遗传病因会导致急性和慢性(以及潜在的不可逆转)呼吸衰竭。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号